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Objective: Neoadjuvant therapy is commonly used for esophageal adenocarcinoma.
We have reported reduced local recurrence rates and improved survival after an en
bloc esophagectomy compared with a transhiatal resection as primary therapy for ad-
enocarcinoma of the esophagus. The aim of this study was to determine whether the
benefits of an en bloc resection would extend to patients after neoadjuvant therapy.
Methods: The charts of all patients with esophageal adenocarcinoma that had neoad-
juvant therapy and en bloc or transhiatal esophagectomy from 1992–2005 were re-
viewed. Patients found to have systemic metastatic disease at the time of the
operation or who had an incomplete resection were excluded.
Results: There were 58 patients: 40 had an en bloc resection and 18 had a transhiatal
esophagectomy. A complete pathologic response occurred in 17 (29.3%) of 58 pa-
tients. Median follow-up was 34.1 months after en bloc resection and 18.3 months af-
ter transhiatal resection (P5 .18). Overall survival at 5 years and survival in patients
with residual disease after neoadjuvant therapy was significantly better with an en bloc
resection (overall survival: 51% for en bloc resection and 22% for transhiatal resection
[P 5 .04]; survival with residual disease: 48% for en bloc resection and 9% for tran-
shiatal resection [P 5 .02]). Survival in patients with complete pathologic response
tended to be better after an en bloc resection (en bloc, 70%; transhiatal, 43%; P5 .3).
Conclusion: An en bloc resection provides a survival advantage to patients after neo-
adjuvant therapy compared with a transhiatal resection, particularly for those with
residual disease. Similar to patients treated with primary resection, an en bloc esoph-
agectomy is the procedure of choice after neoadjuvant therapy.
T
he incidence of adenocarcinoma of the esophagus and esophagogastric junc-
tion is increasing faster than any other cancer in the Western world.1 Although
survival is excellent in patients with early-stage tumors, unfortunately, most
patients present with dysphagia and have locally advanced disease. The prognosis
for these patients is poor, and consequently, attention has focused on the use of neo-
adjuvant therapy in an effort to reduce the local-regional tumor burden and eradicate
micrometastatic systemic disease. During the past 2 decades, neoadjuvant chemora-
diotherapy has been tested in numerous trials, and although a clear improvement in
overall survival compared with that after surgical resection alone has not been dem-
onstrated, subgroup analysis has suggested that patients who obtain a complete path-
ologic response have improved survival compared with those who have residual
disease at the time of resection.2 This finding has prompted some oncologists to rec-
ommend eliminating surgical resection after neoadjuvant therapy because it is thought
that those with complete pathologic response do not need resection and those with in-
complete response have such a poor prognosis that they are unlikely to benefit from
the operation.
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It has been our policy to reserve neoadjuvant therapy for
patients with locally advanced disease based on findings
from computed tomographic (CT) scans, endoscopic ultraso-
nographic analysis, and/or positron emission tomographic
(PET) scanning. After neoadjuvant therapy, we have taken
fit patients for an en bloc resection, given evidence that local
recurrence is minimized and survival is maximized with this
procedure in patients who have surgical intervention as the
primary therapy for their cancer.3 The aim of this study
was to review our experience and determine whether the local
control and survival benefits of an en bloc esophagectomy
would extend to patients after neoadjuvant therapy and in
particular to those with residual disease on final pathology.
Materials and Methods
Patient Population
The study population was drawn from all patients who had an esoph-
agectomy for adenocarcinoma between 1993 and 2005 at the Uni-
versity of Southern California. Assessment of the extent of disease
before surgical intervention included upper endoscopy, a chest
and abdominal CT scan, and, when it became available, endoscopic
ultrasonographic analysis (1997) and PET or CT–PET scanning
(1998). Patients were considered to have advanced local-regional
disease when there was evidence of multiple (.4) enlarged lymph
nodes based on endoscopic ultrasonographic analysis. In patients
who did not (unavailable) or could not (because of the size of the tu-
mor) undergo endoscopic ultrasonography, a diagnosis of advanced
local-regional disease was based on the endoscopic size and length
of the tumor, CT scan evidence of a bulky tumor with or without
enlarged peritumoral nodes, and/or PET scan findings consistent
with multiple involved lymph nodes.
The records of all patients who had neoadjuvant therapy fol-
lowed by an en bloc or a transhiatal esophagectomy for esophageal
adenocarcinoma were reviewed. Neoadjuvant therapy was chemo-
therapy alone or chemoradiotherapy. Chemotherapy consisted of
standard agents, including 5-fluorouracil, cisplatin, carboplatin,
and/or paclitaxel. Patients were excluded if they were found to
have systemic metastatic disease at the time of the operation, had
a tumor that penetrated into an adjacent organ (T4), or had an incom-
plete pathologic resection (R1). In addition, patients who had an op-
eration other than an en bloc or transhiatal esophagectomy were
excluded. This study was approved by the Institutional Review
Board of the University of Southern California.
En bloc esophagectomy was performed in patients who were
younger than 75 years and who were free of substantial medical co-
morbidities. Transhiatal esophagectomy was performed in patients
75 years or older and those with significant cardiac or pulmonary
disease or other major comorbid conditions. Patients were followed
by the operating surgeon at regularly scheduled intervals (every 3
months for the first 3 years, every 6 months up to 5 years, and yearlyThe Journal of Thorathereafter). CT scans of the chest and abdomen and routine blood
chemistry results were obtained at each visit, and PET scans were
obtained yearly.
Surgical Treatment
En bloc esophagectomy was performed as described in previous
publications.4 In brief, the en bloc dissection was performed through
a right seventh-interspace posterolateral thoracotomy to have excel-
lent exposure of the potentially involved mediastinal nodes below
the carina, an upper midline laparotomy, and a left neck incision.
The thoracic dissection removed en bloc the esophagus, azygos
vein, thoracic duct, and surrounding lymph node–bearing mediasti-
nal tissues. The borders of the dissection extend superiorly to above
the azygos arch; laterally to include the left and right mediastinal pa-
rietal pleura; anteriorly to the membranous trachea, pericardium,
and diaphragm; posteriorly to the spine and aorta; and inferiorly
to the esophageal hiatus and down into the costal vertebral angle.
Above the aortic arch, the dissection is kept adjacent to the esopha-
gus to minimize potential injury to the recurrent laryngeal nerve. A
paratracheal node dissection is not routinely performed for adeno-
carcinoma of the distal esophagus or gastroesophageal junction.
The abdominal dissection was performed through an upper midline
incision and removed the node-bearing tissue from the lateral sur-
face of the right crus, the porta hepatis, and around the portal vein
and the common hepatic, celiac, and left gastric arteries. Addition-
ally, node-bearing tissue was removed from the lateral surface of
the left crus, around the splenic artery, medial to the splenic hilum,
and anterior to the adrenal gland. The en bloc dissection allowed
systematic removal of lymph nodes in the following areas: low para-
tracheal, subcarinal, perihilar, paraesophageal, parahiatal, costal-
vertebral space, porta hepatis, superior retropancreatic, and around
the portal vein and the hepatic, celiac, and splenic arteries.
Transhiatal dissection was performed as described by Orringer5
through an upper midline incision and a left neck incision. The lower
mediastinal and esophageal dissectionwas performed through awid-
ened diaphragmatic hiatus by using blunt and sharp dissection. Para-
esophageal and mediastinal lymph nodes were removed as exposure
allowed, but a complete node dissection in the mediastinum was not
possible. The abdominal node dissection was identical to that
described for the abdominal portion of the en bloc procedure.
Reconstruction in most patients was with a tubularized gastric
pull-up, but if the stomach was unavailable or unsuitable, a colon in-
terposition was performed. Reconstructions were preferentially
placed in the posterior mediastinum, and the proximal anastomosis
was hand sewn in the neck.
Statistical Analysis
Grouped data were expressed as medians with interquartile ranges.
Statistical analysis appropriate for nonparametric data was used.
Univariate analyses were performed by using the Fisher exact
test for categorical variables and the Mann–Whitney test for contin-
uous variables. Survival was calculated by using the Kaplan–Meier
method, with comparisons of survival by means of the log-rank
test.
Results
From January 1993 through August 2005, 416 patients with
esophageal adenocarcinoma were seen by members of thecic and Cardiovascular Surgery c Volume 135, Number 6 1229
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Southern California. From this group, 323 (78%) patients
underwent primary surgical resection, and 92 (22%) patients
had neoadjuvant therapy before resection. Among
patients who had neoadjuvant therapy, 6 presented late for
salvage resection with known recurrent disease, 14 under-
went a procedure other than an en bloc or transhiatal resection
(7 minimally invasive and 6 Ivor–Lewis or non–en bloc
transthoracic resections), 7 were found to have metastatic
disease at the time of operation, 3 had an incomplete (R1)
resection, and 3 patients died perioperatively (2 en bloc and
1 transhiatal). These patients were excluded. Therefore the
final study population was composed of 58 patients: an en
bloc resection was performed in 40 patients, and a transhiatal
resection was performed in 18 patients. Reconstruction was
with a gastric pull-up in 93% of patients, with colon interpo-
sition performed after en bloc resection in 3 patients and
after transhiatal resection in 1 patient. Clinical data are sum-
marized in Table 1. The median radiation dose was 40 Gy in
each group, and approximately 90% of patients in each group
had both chemotherapy and radiotherapy. Furthermore,
chemotherapy was standard cisplatin and 5-fluorouracil in
93% of patients undergoing en bloc resection and 83% of
patients undergoing transhiatal resection (P 5 .36).
TABLE 1. Characteristics of the study population
Characteristic
Transhiatal
esophagectomy
group (n 5 18)
En bloc
esophagectomy
group (n 5 40)
P
value
Sex, F/M 2/16 5/35 1.0
Age, y 64 (59–74.5) 54.5 (49–61) .0009
BMI 27.05 (24.95–29.8) 27.3 (24.6–29) .76
ASA score 3 3 .437
Comorbidity
Any 15 (83%) 11 (27.5%) .0001
 Diabetes 1 2
 Hypertension 5 6
 Cardiovascular 10 4
 Pulmonary 4 2
Tumor location*
Distal
esophagus/GEJ
88%/12% 90%/10% 1.0
Presence of
Barrett's
esophagus
22% 28% .76
Chemotherapy only 2/18 (11.1%) 2/40 (5%) .58
Chemoradiotherapy 16/18 (88.9%) 38/40 (95%)
Radiation dose, Gy 40 (35.5–40) 40 (40–45) .14
All values are presented as medians and interquartile ranges. BMI, Body
mass index;ASA, American Society of Anesthesiologists;GEJ, gastroesoph-
ageal junction. *Information allowing determination of a distal esophageal
versus a gastroesophageal junction tumor was available on 9 patients un-
dergoing transhiatal resection and 20 patients undergoing en bloc resection.1230 The Journal of Thoracic and Cardiovascular Surgery c JuComplete pathologic response occurred in 17 (29.3%) of
58 patients and was more common in the transhiatal group.
Details of the final pathology are shown in Table 2. The final
pathologic stage was similar in both groups, but stage 3 tu-
mors tended to be more prevalent in the en bloc group
(37.5% for en bloc resection vs 28% for transhiatal resection,
P5 .6). The majority of patients in both groups had residual
cancer in the resected esophagus. Furthermore, residual can-
cer was found in both the esophagus and at least 1 lymph
node in 67% of patients. In those with no residual cancer in
the esophagus (n 5 19), only 2 (10.5%) patients had 1 or
more involved lymph nodes.
Median follow-up tended to be longer in patients who had
an en bloc resection (en bloc, 34.1 months; transhiatal, 18.3
months; P 5 .18). Recurrence of any type occurred in 18
(45%) patients who had an en bloc resection compared
with 13 (68%) patients who had a transhiatal resection
(P 5 .087) at a median of 8.5 months. The recurrence was
systemic in the majority of patients (Table 3). The prevalence
of local-regional recurrence was significantly reduced in
patients who had an en bloc resection.
Overall survival at 5 years was significantly better in pa-
tients who had an en bloc compared with a transhiatal
esophagectomy after neoadjuvant therapy (51% vs 22%, re-
spectively; Figure 1). There were 4 non–cancer-related
deaths during follow-up: 3 in the en bloc group and 1 in
the transhiatal group. If survival is compared by using
only cancer-related deaths, the improvement with the en
bloc resection is even more significant (56% for en bloc
vs 25% for transhiatal at 5 years, P 5 .03). In patients
with a complete pathologic response, there was a trend to-
ward improved 5-year survival with an en bloc resection
compared with that after a transhiatal resection (en bloc,
70%; transhiatal, 43%; P 5 .3; Figure 2). Survival in pa-
tients with residual disease was significantly better after an
en bloc resection compared with that after transhiatal resec-
tion (48% vs 9%, respectively; P 5 .02; Figure 3). Among
the 30 patients with residual disease after neoadjuvant ther-
apy who had an en bloc resection, there were 17 patients op-
erated on more than 5 years ago, and from this group, 6 were
alive, for an absolute 5-year survival of 35%. In contrast, 8
patients had a transhiatal esophagectomy after neoadjuvant
therapy more than 5 years ago, and no patient survived
for 5 years (longest survival, 38.5 months).
Discussion
The treatment of locally advanced esophageal adenocarci-
noma is difficult, and survival is often poor in these patients
from either local-regional failure, development of systemic
disease, or both. In an effort to improve survival, chemoradio-
therapy has been given before surgical resection, and although
many phase 2 studies suggested a benefit with this approach,
the results from randomized prospective trials, as well as
a large-population based study, have been disappointing.2,6ne 2008
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Characteristics
Transhiatal esophagectomy
group (n 5 18)
En bloc esophagectomy
group (n 5 40) P value
Stage 0 7 10
Stage I 3 3
Stage IIA 1 8
Stage IIB 2 4
Stage III 5 15
Complete pathologic response 7/18 (39%) 10/40 (25%) .35
Residual disease in the esophagus (%) 10/18 (56%) 29/40 (73%) .23
Residual disease (esophagus or nodes) 11/18 (61%) 30/40 (75%) .35
Residual tumor size, cm 1.75 (0–5.5) 3 (0–5) .56
Nodes removed 19 (13.5–29) 29.5 (24.5–44.5) .0016
Patients with at least 1 involved node (%) 7/18 (38.8%) 19/40 (47.5%) .58
Involved nodes
Median 0 (0–4) 0 (0–3) .64
Mean 3.5 3.2
Distribution of involved nodes (%)
Abdominal and mediastinal 2/7 (28.5%) 9/19 (47.4%)
Mediastinal only 0 1/19 (5.2%)
Abdominal only 5/7 (71.4%) 9/19 (47.4%)
Values are presented as medians and interquartile ranges.The only randomized trial to show improved survival with
preoperative chemoradiotherapy was published by Walsh
and colleagues,7 but this trial has been dismissed by many be-
cause of the lack of appropriate staging, methodological
flaws, and most importantly survival curves that do not match
the data in the text.2,7,8 Trials from England have suggested
a benefit from preoperative chemotherapy alone, but these tri-
als also suffer from methodological flaws, and similar results
were not found in a major US trial.9,10 The most encouraging
results of these trials has been that patients that have a com-
plete pathologic response appear to have improved survival,
with most series reporting about 50% five-year survival in
this subgroup.11,12 Because overall survival is similar to that
of patients treated with resection alone, this would imply
that patients who do not have a complete pathologic response
to therapy have worse survival than similarly staged patients
treated with primary esophagectomy, and this has been sub-
stantiated in a number of reports.6,13 The survival after resec-tion in patientswith residual disease after neoadjuvant therapy
has been so poor that some oncologists and surgeons question
the role of esophagectomy in this group.
We and others have reported excellent survival in patients
with esophageal adenocarcinoma treated with primary en
bloc resection, and in similarly staged patients with limited
lymph node involvement, we have shown that survival was
improved with the en bloc compared with the transhiatal
esophagectomy.14-18 However, criticism regarding stage mi-
gration and patient selection, as well as the complexity of the
en bloc operation, has hampered widespread acceptance of
this procedure. The aim of this study was to compare the ef-
fect of the type of resection in a group of patients with locally
advanced esophageal adenocarcinoma all treated with neoad-
juvant therapy. Similar to our experience with primary resec-
tion, we found that overall survival after neoadjuvant therapy
was significantly better in patients who had an en bloc com-
pared with a transhiatal esophagectomy. Our 22% five-yearTABLE 3. Recurrence pattern after esophagectomy related to operative approach
Transhiatal esophagectomy
group (n 5 18)
En bloc
esophagectomy group (n 5 40)
cPR RD Total cPR RD Total P value*
Any recurrence (%) 3 10 13 (68%) 2 17 19 (47.5%) .095
Systemic 2 7 9 (50%) 2 16 18 (45%) .78
Local-regional 0 3 3 (16.6%) 0 0 0 .023
Neck 1 0 1 (5.5%) 0 1 1 (2.5%) .51
cPR, Complete pathologic response; RD, residual disease. *The P value was calculated for the total number of recurrences between groups.
The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 6 1231
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is similar to what has been reported by others.6,11 This simi-
larity confirms that although our transhiatal group of 18 pa-
tients is small, there is no reason to believe that larger
numbers would substantially alter our results, and that the
significant difference we found in favor of the en bloc resec-
tion is valid. The few non–cancer-related deaths in this pop-
ulation of patients indicate that regardless of comorbidities,
the most likely cause of death in patients treated for locally
advanced esophageal adenocarcinoma is recurrent cancer,
and even after neoadjuvant therapy, the extent of resection
is still an important determinant of ultimate survival from
this disease.
The improved survival with an en bloc resection is likely
due to the high frequency of involved lymph nodes both in
the mediastinum and abdomen after neoadjuvant therapy
and the fact that a systematic lymphadenectomy allows re-
moval of both known and unknown (micrometastatic) dis-
ease. This is also the likely explanation for why survival
steadily improves with an increasing number of lymph nodes
removed in patients with esophageal cancer (data not shown).
This same correlation for increasing survival with an increas-
ing number of resected nodes has previously been shown to
be true for gastric cancer.19 Resection of potentially involved
lymph nodes is important, even after neoadjuvant therapy,
because Prenzel and colleagues20 have shown that neoadju-
vant therapy does not reliably eliminate lymph node disease.
Figure 1. Kaplan–Meier survival curve for all patients and all-
cause mortality. Overall survival is significantly better in the pa-
tients who had an en bloc resection compared with those who
had a transhiatal resection after neoadjuvant therapy. Note that
the 5-year survival of 22% for the patients who had a transhiatal
resection is similar to that seen in previous reports.11 Absolute
5-year survival was 11 (50%) of 22 for patients who had an en
bloc resection compared with 3 (23%) of 13 for patients who had
a transhiatal resection (P5 .28). THE, Transhiatal esophagectomy.1232 The Journal of Thoracic and Cardiovascular Surgery c JunThese authors used both routine histology and immunohisto-
chemistry to evaluate for micrometastatic nodal disease and
reported that after neoadjuvant therapy, 75% of patients
have nodal metastases. The high prevalence of residual nodal
disease emphasizes the importance of complete node dissec-
tion and almost certainly explains our finding of improved
survival with an en bloc resection, particularly because the
incidence of systemic disease was similar in our en bloc
and transhiatal resection groups.
Given the failure of randomized trials to demonstrate
a clear survival advantage for all patients treated with neoad-
juvant therapy before surgical resection, attention has fo-
cused on the subgroup of patients with complete pathologic
response. We found that complete pathologic response on fi-
nal pathology was present in 29% of patients in this retro-
spective analysis, and as has been previously demonstrated,
these patients had improved survival compared with those
with residual disease. The 5-year survival after complete re-
sponse in patients who had a transhiatal resection was 43%,
which is similar to what has been reported in other series.11
However, the 70% five-year survival with an en bloc resec-
tion in patients with complete pathologic response sets
a new high standard. It is interesting that nodal disease as
the only form of residual disease (no tumor left in the esoph-
agus) was rare. Given this, one would expect that in patients
with complete pathologic response, the type of resection
would not affect survival. However, we found a trend toward
Figure 2. Kaplan–Meier survival curve for patients who had
a complete pathologic response on final pathology. There was
a nonsignificant improvement in survival for patients who had
an en bloc resection. Note that the 5-year survival for patients
who had a transhiatal resection and complete pathologic re-
sponse was 43%, and this again is similar to published results.11
Absolute 5-year survival was 5 (100%) of 5 in the en bloc group ver-
sus 3 (60%) of 5 in the transhiatal group (P5 .44). THE, Transhiatal
esophagectomy.e 2008
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and with larger numbers, the difference might have been sig-
nificant (type 2 error). It is likely that the en bloc resection is
removing unknown micrometastatic nodal disease in these
patients. This concept is supported by studies using immuno-
histochemistry to identify micrometastases in lymph nodes,
such as one by Prenzel and colleagues,20 in which 41% of pa-
tients thought to be node negative based on routine histology
had micrometastases. This emphasizes the inaccuracy of only
using routine histology to evaluate for complete pathologic
response and reinforces the importance of a systematic lym-
phadenectomy to remove microscopic residual disease, pre-
vent recurrence, and maximize survival, even in patients
thought to be complete pathologic responders.
The most important finding in this study was that there
was a significant improvement in survival with an en bloc re-
section compared with that with a transhiatal resection in pa-
tients with residual disease after neoadjuvant therapy and that
the 48% five-year survival with en bloc esophagectomy jus-
tifies resection in these patients. Even when absolute survival
is considered, we found that at 5 years, 35% of patients with
residual disease were alive after an en bloc resection com-
pared with 0 patients in the transhiatal group. The fact that
these patients all had residual disease eliminates concerns re-
garding stage shift or differences in the extent of disease ac-
counting for the improved survival in the en bloc group and
confirms that the extent of resection directly affects the likeli-
hood of survival from esophageal adenocarcinoma. The 9%
Figure 3. Kaplan–Meier survival curve for patients who had resid-
ual disease after neoadjuvant therapy on final pathology. Survival
was significantly improved in the patients who had an en bloc re-
section compared with those who had a transhiatal resection. Ab-
solute survival was 6 (35%) of 17 with an en bloc resection
compared with 0 (0%) of 8 with a transhiatal resection (P 5 .1).
THE, Transhiatal esophagectomy.The Journal of Thorasurvival after transhiatal resection we observed in patients
with residual disease is similar to the 12% survival reported
for this group in the University of Michigan trial, and there-
fore it is not that our patients with residual disease who have
a transhiatal resection are doing worse than expected. Rather,
the clear message from our data is how well patients do long-
term with an en bloc resection after neoadjuvant therapy,
even in the setting of residual disease. These data should dis-
courage the dismissal of the group with residual disease as
incurable and encourage a systematic lymphadenectomy
and complete resection to enable a chance for cure in these
patients. However, in patients with residual disease, a tran-
shiatal resection should not be routinely offered, given the
poor survival with this operation in these patients.
The primary goal of surgical resection is complete disease
removal in an effort to minimize local-regional recurrence,
and we have previously shown that the en bloc technique is
associated with a 1% local-regional failure rate.14 In contrast,
local-regional failure rates with transhiatal resection are 30%
to 40% in series from around the world.11,21,22 The major ef-
fect of neoadjuvant therapy appears to be an improvement in
local regional disease control without a reduction in systemic
disease. In the randomized trial from the University of Mich-
igan, local-regional disease recurrence was reduced from
42% in the transhiatal resection–only group to 19% in the
neoadjuvant therapy group.11 The prevalence of local-
regional failure after neoadjuvant therapy and transhiatal
resection in our experience was similar at 16.6%. However,
this is significantly higher than the complete absence of local
regional failure we observed in patients who had an en bloc
resection after neoadjuvant therapy. The similar low local-
regional failure rate with the en bloc esophagectomy, whether
done as primary therapy or after neoadjuvant therapy, calls
into question the utility of neoadjuvant therapy for local con-
trol unless a transhiatal operation is the only option for the
patient. Similar to reports from the randomized trials of neo-
adjuvant therapy, we noted that the majority of recurrences
were systemic, despite the administration of neoadjuvant
therapy, and this frustrating fact represents a clear challenge
for the oncology community and should encourage adoption
of new approaches for this daunting disease, including con-
sideration of long-term, low-dose adjuvant chemotherapy ad-
ministration and chemosensitivity-directed chemotherapy
protocols.
The shortcomings of this study include that it is retrospec-
tive and that the selection of patients for a transhiatal resec-
tion was based on advanced age and medical comorbidities.
However, several facts show these shortcomings to be of mi-
nor significance. First, the survival and local-regional recur-
rence rates we report for the patients undergoing transhiatal
resection are very similar to the results from randomized trials
and from a large population-based database.6,11,12 Further-
more, the major cause of death in these patients was cancer,
with only a single death in the transhiatal group occurringcic and Cardiovascular Surgery c Volume 135, Number 6 1233
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garding the significantly increased age and comorbidities in
the transhiatal group affecting survival are unfounded, and
an analysis of only cancer-related deaths merely strengthens
the significance of our findings. Another issue is that we de-
liberately did not provide preoperative staging information
because clinical staging for esophageal cancer is poor. How-
ever, our bias is to perform primary en bloc resection in
patients with limited local-regional disease. Patients with lo-
cally advanced tumors with multiple nodes on endoscopic
ultrasonographic analysis or PET scanning are referred for
neoadjuvant therapy, and the decision for an en bloc versus
transhiatal resection after neoadjuvant therapy is not based
on response but is made purely on the basis of the age, comor-
bid conditions, and cardiopulmonary status of the patient. If
anything, in this study the deck was stacked against the en
bloc group, where follow-up was longest, fewer patients
had a complete pathologic response, and 68% had stage 2
or 3 disease compared with 44% in the transhiatal group after
therapy. Thus the survival differences we demonstrated are
unlikely to be due to substantial differences in preoperative
stage between the en bloc and transhiatal groups or as a result
of the selection of patients with the best response to neoadju-
vant therapy for an en bloc resection. Lastly, despite the dif-
ferences between groups in regard to age and comorbidities,
we found no evidence that the neoadjuvant therapy differed
significantly between groups, with the majority of patients
receiving standard chemotherapy and radiotherapy.
In conclusion, in this study of patients with locally ad-
vanced adenocarcinoma of the esophagus, all of whom
were treated with neoadjuvant therapy, there was a significant
improvement in overall survival and survival with residual
disease in patients who had an en bloc esophagectomy com-
pared with those who had a transhiatal resection. Clearly,
even after neoadjuvant therapy, the extent of resection is an
important determinant of long-term survival from esophageal
adenocarcinoma. The explanation for this finding relates to
the higher local-regional failure rate with a transhiatal resec-
tion and likely to the removal of both known and unknown
(micrometastatic) disease with the extended lymphadenec-
tomy that is performed with the en bloc procedure. Poor sur-
vival with a transhiatal resection in patients with residual
disease mandates an en bloc resection in this group, and the
improved survival overall shouldmake an en bloc esophagec-
tomy the procedure of choice in all patients after neoadjuvant
therapy. Further improvements in survival with this deadly
disease will require chemotherapy agents and protocols that
are able to reduce the incidence of systemic recurrence and
represent a major challenge for the oncology community.
However, these compelling data proving the superiority of
the en bloc resection in patients who have had neoadjuvant
therapy should finally put to rest the question of whether an
extended resection is necessary, beneficial, or both for the
treatment of patients with adenocarcinoma of the esophagus.1234 The Journal of Thoracic and Cardiovascular Surgery c JuReferences
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Discussion
Dr Richard I. Whyte (Stanford, Calif). First, I would like to con-
gratulate Dr Rizzetto on a very interesting and well-presented paperne 2008
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en bloc esophagectomy, and the results of neoadjuvant therapy.
The authors are clearly presenting some very impressive results
here in terms of a 70% five-year survival in the 25% of patients who
were complete pathologic responders. That is really sort of best in
class. Also, they really demonstrate the fact that en bloc resection
results in a very low local recurrence rate.
I have 2 or 3 questions, however, and I think Dr DeMeester is
going to address those.
First, you have described candidates for neoadjuvant therapy as
having locally advanced disease proved by both endoscopic ultraso-
nographic analysis and PET scans, yet there are no data in the pre-
sentation or in the manuscript on the TNM staging of these patients.
Can you provide some information as to their pretreatment TNM
status?
Dr DeMeester. The problem with pretreatment staging is that
the clinical staging for esophageal cancer is terrible. Many of these
patients in the earlier time frame did not undergo PET scans or en-
doscopic ultrasonography. We do that routinely now, and as you
know, our preference is primary surgical resection in anyone who
we think has limited local regional disease, which for us, is patients
who had any depth of tumor with less than 5 obvious nodes deter-
mined by means of endoscopic ultrasonographic analysis or PET
scan. For anyone with 5 or more nodes, we know that the systemic
failure rate with surgical intervention alone in our experience ex-
ceeds 80%, and therefore those patients will need chemotherapy ei-
ther before or after surgical intervention. We talk to the patient about
that, and many of these patients are selected then to have preopera-
tive chemoradiotherapy, followed by surgical intervention. All of
our patients who have neoadjuvant therapy have extensive local-re-
gional disease. In fact, if you look at the final pathologic staging,
some 60% of the en bloc group had stage II or III disease after neo-
adjuvant therapy, and therefore the majority of these patients started
with significant disease.
DrWhyte. My next question sort of relates to how patients were
assigned to receive an en bloc resection or a transhiatal resection. In
the presentation we heard that there is use of the number of lymph
nodes to sort of ascribe one operation versus another. However, in
the manuscript you talk about it both being related to the age and
the presence or absence of comorbidities. I am a little confused
then as to whether you used the presence or absence of lymph nodes
or the number of lymph nodes to help determine whether patients
receive an en bloc resection or a transhiatal resection.
Dr DeMeester. I am sorry if that was confusing in the presenta-
tion. We are merely demonstrating that, as should be no surprise, en
bloc resection removes far more lymph nodes than transhiatal resec-
tion, but the number of lymph nodes has nothing to do with the se-
lection of the operation. The operation is selected on our assessment
of the patient’s physiologic ability to withstand an en bloc proce-
dure, which is a bigger deal, and therefore patients who are older
than 70 or 75 years and have any renal, cardiac, or pulmonary dys-
function are selected for a transhiatal resection. That then brings in
the concern that patients in the transhiatal group have higher comor-
bidities and are dying off as a consequence of these comorbidities
and not their cancer. We also prepared cancer-only survival statistics
and have demonstrated that the statistics and the significance be-
tween the curves are the same. In fact, all deaths, except for one
in the transhiatal group, were from cancer. Therefore the comorbid-The Journal of Thoraities are what we use to select the procedures, but that had no effect
on the outcome from the procedures.
DrWhyte. So you are not using the presence or absence of nodal
disease or the number of nodes to assign someone to en bloc versus
transhiatal resection.
Dr DeMeester. No. We use the number of nodes to determine
whether we should select patients for neoadjuvant therapy, but
that has nothing to do with whether we select them for transhiatal
or en bloc resection. Our preference is always en bloc resection,
but we will downstep to a transhiatal resection in patients who we
fear will not handle the en bloc resection based on comorbidities.
DrWhyte. My last question then is this: Why don’t you do an en
bloc resection on everyone? Your mortalities are pretty similar. In
terms of the ASA class you presented, they are roughly the same
in the transhiatal versus the en bloc resection. As for the presence
or absence of comorbidities, the numbers are fairly similar. You
had 11 of 40 patients who had significant comorbidities in your en
bloc resection group. I am thinking that persons who undergo a tran-
shiatal resection have a laparotomy, a gastric mobilization, a pretty
extensive mediastinal dissection, and then a neck incision, and the
patients undergoing en bloc resection get a bit more extensive ab-
dominal dissection and then perhaps a rather limited thoracotomy
but, in addition, a much more precise mediastinal dissection. I am
wondering why you do not do an en bloc esophagectomy in every-
one, particularly because you are clearly convinced it is the right op-
eration. Your data indicate that they have better long-term survival,
and the mortalities are somewhat similar. Why not do an en bloc re-
section on everyone? Then we can really see—sort of take out this
transhiatal versus en bloc issue—and focus on whether the potential
increased morbidity of the bigger operation is more than made up for
by the better long-term survival in these patients.
I really enjoyed the paper, and it was well presented. Thanks very
much.
Dr DeMeester. We are pretty much coming to that same conclu-
sion. Essentially everyone who comes for primary surgical resection
has an en bloc resection at this point. I have done 1 transhiatal resec-
tion maybe in the last 3 years, and that was in a guy who had a pre-
vious pneumonectomy. Therefore essentially everyone gets an en
bloc resection for primary therapy. Part of this experience now is
teaching us that even after neoadjuvant therapy, we need to push
the en bloc resection because part of our attitude initially, as I think
was present in many surgeons, was that if you had neoadjuvant ther-
apy, that was supposed to take care of the problem, and you could
probably just get by with a transhiatal resection. Therefore 5 or 10
years ago, when we were first doing this, often we would do a tran-
shiatal resection in a patient who could have had an en bloc resec-
tion, but we thought they have had neoadjuvant therapy, the
chemoradiation increases the potential morbidity particularly for
a thoracotomy, more respiratory complications, maybe it is not
worth doing that. These data now will tell us that anybody who
comes with neoadjuvant therapy at USCwill get an en bloc resection
if at all possible.
Dr Robert Cerfolio (Birmingham, Ala). Steve, excellent work. I
congratulate you and your efforts to continue to collect prospective
data on esophageal cancer. It is a lot of work, and we appreciate
everything you have contributed to the field and to our patients.
This thing about complete responders—the only way to know
who is a complete responder is to take the cancer out and look.cic and Cardiovascular Surgery c Volume 135, Number 6 1235
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Lewis esophagogastrectomy, as you do—and have shown that the
change in the maximal standardized uptake value helps predict
who will be a complete responder and who will not. When the pri-
mary tumor decreases by greater than 75%, that patient is very
likely—has a greater than 90% chance of being a complete re-
sponder. I am wondering whether you have any data that would cor-
roborate that, and then, if you do, if you would comment on the fact
that I get a lot of medical oncologists who say, ‘‘If he is a complete
responder, he does not need surgery.’’ The ones who refuse or de-
cline it because they are a ‘‘complete responder’’ all seem to return
within 9 to 12 months with bad local and often distant metastatic dis-
ease. Can you tell me how you respond to your oncologists and push
the patient to get the operation and if you havemaximal standardized
uptake value data?
Dr DeMeester. We are just starting to look at some of the max-
imal standardized uptake value data. We do not certainly have that
going back in this study population, particularly because a number
of these patients had their operations before PET scans were widely
used. I will say, though, that I am not convinced that PET scanning is
ever going to get down to the level of the cell. There is just no chance
that you are going to predict 100% of the time who has no residual
cancer. I do not think there is any test short of the pathologist with
his microscope sorting that out. The reality is, if you leave cancer
behind, the patients are going to die from their cancer. It is going
to come back. Therefore I do not see a way with any of our current
studies to rule out or to find those patients who do not need surgical
intervention because of complete pathologic response. We know
that the mucosal disease clears up first. If you cannot clear mucosal
disease with neoadjuvant therapy, then you have real problems. In
our data 60% of patients had residual disease in the esophagus,
and therefore the majority of patients do, and it should be resected
with an en bloc procedure.
Dr Cerfolio. Therefore you tell the oncologists that you do not
know whether the patients are complete responders no matter what
their repeat endoscopic ultrasonographic tests and repeat PET scans
show, and thus you, like us, recommend surgical resection.
Dr DeMeester. Repeat endoscopic ultrasonography has been
shown to be of no value after neoadjuvant therapy, and therefore I
do not even offer it. I tell the oncologists that 60% of these patients
have residual disease in the esophagus and 40% will have nodal dis-
ease, and if you read a recent article by Prenzel using immunohisto-
chemistry, 75% of patients after neoadjuvant therapy have either
histologic or immunohistochemical evidence of nodal disease.
The vast majority of these patients have disease and should have
an esophagectomy. Now the issue you brought forward is that
many oncologists have taken an approach that surgical intervention
should not be offered after neoadjuvant therapy because if you get
a complete pathologic response, your survival is pretty good, and
if you did not and you get a transhiatal resection, your survival is
horrible, and therefore why should they undergo an operation at
all after neoadjuvant therapy? That is the emphasis of this paper.
Your survival is not horrible if you do a good operation. Fifty per-
cent of patients were alive at 5 years after neoadjuvant therapy
with an en bloc resection, and even with residual disease, it was
an impressive survival. These patients should have an esophagec-
tomy, and it should be en bloc.1236 The Journal of Thoracic and Cardiovascular Surgery c JuDr Cerfolio. Our data are similar, and we agree.
Dr David Follette (Sacramento, Calif). Steven, I enjoyed your
paper, and it is one of the first to corroborate some data from East
Germany regarding complete responders and survival in squamous
cell carcinoma of the esophagus, which we do not see that much of
anymore. We really still do not know the benefit of neoadjuvant
therapy because the Walsh study is one of the only ones to show
the advantage and, as was mentioned in the talk, is severely flawed.
In my mind, what is coming to the fore is this issue of a complete
response or a partial response. We have seen good long-term sur-
vival in persons who are nonresponders to neoadjuvant therapy
with good survival rates with just definitive chemotherapy and radi-
ation therapy. My question is, you briefly mentioned to Rob that you
do not do repeat ultrasonographic analysis on these persons, but do
you use CT scanning restaging after neoadjuvant, and if they are
nonresponders or if the tumor is fed and growing with the neoadju-
vant, how do you handle that group of patients?
DrDeMeester. We definitely restage them, looking for systemic
disease. If a patient has systemic disease, we do not offer him or her
esophagectomy. If the patient does not have systemic disease, the
extent of the local regional disease does not dissuade me from mov-
ing forward. It is important to separate out squamous tumors from
adenocarcinomas. All these were adenocarcinomas. You cannot re-
ally do an en bloc resection for squamous tumors. You have milli-
meters between the trachea and major vessels, and therefore it is
a completely different disease, and for those patients, I think defin-
itive chemoradiotherapy often is an advantage. It is totally different
for a distal esophageal adenocarcinoma. Most Americans have cen-
timeters of fat between any significant structure and the esophagus,
and you can get a very excellent resection and take out the lymph
nodes, and there is no comparison between the results of good oper-
ations and definitive chemoradiotherapy in patients with distal
esophageal adenocarcinoma.
DrAlex Little (Dayton, Ohio). I have one quick follow-up ques-
tion to something that was put before. Is the difference in the oper-
ation because of the extent of the abdominal dissection or because
there was not a thoracic nodal dissection?
Dr DeMeester. It is brought out in the manuscript, but our ab-
dominal dissection is identical whether you have a transhiatal or
an en bloc resection, and therefore it is the mediastinal dissection.
As you saw, about 45% of patients had mediastinal and abdominal
nodes in the en bloc group, and therefore there is a high prevalence
of mediastinal nodes that I just do not think you can clear well, lead-
ing to the higher recurrence rate and the failure of survival in the
transhiatal group.
Dr Little. If I might, I have one quick comment to ask you to re-
act to, and it has already been alluded to. I think fully convincing
evidence will not be put before us until all comers are randomized:
to compare a relatively fit with a relatively unfit group sort of stacks
the deck ahead of time.
Dr DeMeester. That would be true if they were dying from their
comorbidities, but as I said, there was 1 death from comorbidities,
a non–cancer-related death, in the transhiatal group. All the rest of
the deaths were from cancer, and if we analyzed it based on can-
cer-related deaths only, the statistical significance is actually even
greater. In my mind the issue is closed. It is decided. The argument
is over. En bloc esophagectomy is superior to a transhiatal resection.ne 2008
